Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16171239 | 1.00 | MDM2 (0.41) | MDM2GAAL3MBTL1IRAK4DRD2 | |
| SCHEMBL681668 | 1.00 | — | — | |
| SCHEMBL2600363 | 1.00 | MDM2 (0.41) | MDM2GAAL3MBTL1IRAK4DRD2 | |
| Hydrochloric Acid SCHEMBL15847512 | 0.97 | — | — | |
| SCHEMBL23487048 | 0.91 | ALDH1A1 (0.45) | MDM2GAAL3MBTL1IRAK4DRD2 | |
| SCHEMBL25069713 | 0.91 | ALDH1A1 (0.45) | MDM2GAAL3MBTL1IRAK4DRD2 | |
| SCHEMBL18684792 | 0.90 | GAA (0.43) | MDM2GAAL3MBTL1IRAK4DRD2 | |
| SCHEMBL104716 | 0.90 | — | — | |
| SCHEMBL104342 | 0.90 | — | — | |
| SCHEMBL10259802 | 0.88 | EPHX1 (0.41) | MDM2GAAL3MBTL1IRAK4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | SYNDEVRX, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230165892-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230048989-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20210128607-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210077452-A1 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUNCTION | SYNDEVRX, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10722532-B2 | Polymer-conjugated METAP2 inhibitors, and therapeutic methods of use thereof | SYNDEVRX, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200155545-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200129457-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | SYNDEVRX, INC. | 2020-04-30 | — | — | US | disclosed |
| US-10588904-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190151353-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. | 2019-05-23 | — | — | US | disclosed |
| US-10010544-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-9895449-B2 | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof | SYNDEVRX, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170326135-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9757373-B2 | MetAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9750737-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9730955-B2 | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof | SYNDEVRX, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9585909-B2 | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof | SYNDEVRX, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20170028014-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10588904-B2 | METAP2 inhibitors and methods of treating obesity | METAP2, ADIPOR2, METAP1 | MDM2 1217/4885GAA 1368/4885L3MBTL1 2313/4885 |
| US-20170028014-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | MDM2 1217/4885GAA 1368/4885L3MBTL1 2313/4885 |
| US-20170326135-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | MDM2 1217/4885GAA 1368/4885L3MBTL1 2313/4885 |
| US-10722532-B2 | Polymer-conjugated METAP2 inhibitors, and therapeutic methods of use thereof | METAP2, MTX2, METAP1 | MDM2 1032/4885GAA 2170/4885L3MBTL1 1118/4885 |
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | METAP2, METAP1, PEBP1 | MDM2 449/4885GAA 2065/4885L3MBTL1 1440/4885 |
| US-20230165892-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | MDM2 1032/4885GAA 2170/4885L3MBTL1 1118/4885 |
| US-20230048989-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | MDM2 1217/4885GAA 1368/4885L3MBTL1 2313/4885 |
| US-20200155545-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | MDM2 1217/4885GAA 1368/4885L3MBTL1 2313/4885 |
| US-20190151353-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | MDM2 1032/4885GAA 2170/4885L3MBTL1 1118/4885 |
| US-20200129457-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | METAP2, METAP1, PCK2 | MDM2 492/4885GAA 1631/4885L3MBTL1 1678/4885 |
| US-20210128607-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | MDM2 1032/4885GAA 2170/4885L3MBTL1 1118/4885 |
| US-20210077452-A1 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUNCTION | PCK2, GOT2, PC | MDM2 648/4885GAA 596/4885L3MBTL1 1272/4885 |
| US-10010544-B2 | METAP2 inhibitors and methods of treating obesity | METAP2, ADIPOR2, METAP1 | MDM2 1217/4885GAA 1368/4885L3MBTL1 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.